The Illinois Wellness Insider
SEE OTHER BRANDS

Informing on health and wellness news in Illinois

ViCentra to Present at Emerging Medtech Summit Europe 2023

UTRECHT, The Netherlands, Sept. 18, 2023 (GLOBE NEWSWIRE) -- ViCentra B.V., the company behind Kaleido, one of the world’s smallest, lightest and most precise Insulin Pump systems for treating people with Diabetes, today announced that Frans Cromme, CEO will provide a corporate update at the Emerging Medtech Summit Europe taking place in Barcelona, Spain, September 18 to 22, 2023.

Presentation Details
Date: Thursday, September 21
Time: 3:05-3:14 pm CET (Track 1)
Location: The Ritz-Carlton Hotel Arts, Barcelona

If you are interested in arranging a one-on-one meeting with management, please contact Leo Toole at ViCentra.

About ViCentra B.V.
ViCentra, the company behind Kaleido is based in the Netherlands. Our philosophy is to make innovative products that put people first. With our focus on diabetes, we develop our products not for patients, but for people. We believe that when products are simple, are designed beautifully, and deliver outstanding results. They provide more user enjoyment and help people live better on their own terms. It was with this philosophy in mind that Kaleido was born. Kaleido is a pioneering insulin delivery system for people with type 1 diabetes. Through its unique pulse technology, it provides extremely precise and reliable delivery of insulin, giving its user the peace of mind and freedom that’s often missing for those with a long term health condition. To learn more about ViCentra, visit the Company’s website at https://hellokaleido.com/.

Company Contacts:
Frans Cromme, CEO
frans.cromme@vicentra.com

Leo Toole, CFO
leo.toole@vicentra.com

Investor Relations Contact:
Michael Wood
LifeSci Advisors
mwood@lifesciadvisors.com


Primary Logo

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service